Baxter FDA Device Footprint: 510(k), PMA, Recall & Manufacturing Analysis

A comprehensive data-driven regulatory profile of Baxter's FDA clearances, PMA approvals, safety recalls, and manufacturing hubs after the Hillrom acquisition.

Executive Summary

What does the FDA database actually reveal about Baxter's medical device clearances, approvals, recalls, and manufacturing footprint?

According to computed aggregates from official FDA databases, Baxter holds 999 active 510(k) clearances, 205 Premarket Approval (PMA) filings and supplements, and 865 associated recalls across its combined operating entities. This regulatory footprint reflects the integration of several major corporate acquisitions, most notably the $10.5 billion acquisition of Hillrom in 2021, which brought Welch Allyn, Novametrix, and specialized ventilation portfolios under the Baxter brand.

An analysis of Baxter's active 510(k) clearances shows a portfolio focused on clinical care consumables, medication delivery, and patient monitoring, led by General Hospital (223 clearances, or 22.3%), Gastroenterology/Urology (185 clearances, or 18.5%), and Cardiovascular (147 clearances, or 14.7%). In the high-risk Class III sector, Baxter holds 205 PMA approvals and supplements, driven by legacy drug-delivery systems and renal-care platforms.

On the safety front, Baxter’s post-market record includes 865 FDA-registered recalls. This volume is led by specialized subsidiaries, including Baxter Healthcare Corporation (373 recalls), the Baxter Renal Division (46 recalls), and Welch Allyn (33 recalls across name variants). The primary root causes of these recalls are process control failures and design anomalies, with a significant concentration of recent Class I safety events involving the Life2000 Ventilation System, which was permanently removed from the market in December 2025 due to a cybersecurity vulnerability. Geographically, Baxter’s registered US manufacturing and listing footprint is anchored in key regional hubs, including Round Lake, Illinois (161 registrations) and Skaneateles Falls, New York (96 registrations).

Baxter FDA Footprint at a Glance

510(k) clearances: 999 (General Hospital 223 / Gastroenterology-Urology 185 / Cardiovascular 147 / Clinical Chemistry 86)
PMA filings and supplements: 205 (focused on specialized drug-delivery systems and automated peritoneal dialysis platforms)
FDA-registered recalls: 865 (led by Baxter Healthcare Corporation — 373, and Baxter Renal Division — 46)
Top US manufacturing hubs: Round Lake, IL (161), Skaneateles Falls, NY (96), Aibonito, PR (53), Batesville, IN (34), Andover, MA (32), Birmingham, AL (31)
International manufacturing hubs: Mexico (60), Malta (55), Dominican Republic (48), Costa Rica (32)
Defining 2025–2026 events: Permanent removal of the Life2000 Ventilation System (Dec 2025) due to cybersecurity; completed divestiture of the Vantive Kidney Care segment to Carlyle ($3.8B, closed January 31, 2026).
Peer comparison position: Leader in renal-care and automated peritoneal dialysis clearances; moderate Class III PMA portfolio compared to cardiology-heavy peers like Medtronic.

Introduction: The Regulatory Scale of Baxter

Baxter International Inc. is a global leader in medical technology, specializing in renal care, medication delivery, clinical nutrition, and surgical products. For hospital procurement offices, clinical engineering groups, and regulatory affairs managers, Baxter is a primary partner, supplying everything from basic IV bags and administration sets to automated peritoneal dialysis systems, infusion pumps, and ICU hospital beds.

Because Baxter operates at such a massive scale, its regulatory footprint is one of the largest and most complex in the FDA databases. To understand this footprint, it must be viewed through the lens of Baxter’s corporate acquisitions and strategic restructurings. Over the past decade, Baxter has transformed its portfolio by acquiring other major medical device manufacturers. The most significant of these was the acquisition of Hillrom in 2021, which added a large patient monitoring, smart hospital bed, and respiratory care portfolio, including the Welch Allyn and Novametrix brands.

This report provides a detailed, data-driven analysis of Baxter's active 510(k) clearances, Premarket Approvals (PMAs), recall history, and global manufacturing establishments. Using computed aggregates from the official FDA databases, we map the specific product codes, recall distributions, and regional hubs that define Baxter's regulatory profile.

How These Numbers Were Computed

The statistics and aggregates presented in this profile are computed from official FDA databases, including the 510(k) database, the Premarket Approval (PMA) database, the Medical Device Recalls database, and the Establishment Registration and Device Listing database. The counts reflect the combined entity of Baxter and its primary subsidiaries, including Hillrom, Welch Allyn, Novametrix, and legacy brand names that remain active applicants in legacy filings.

Because the FDA database retains the applicant name submitted at the time of clearance or approval, queries are designed to capture historical variations, including "Baxter Healthcare," "Hill-Rom," "Welch Allyn," and "Novametrix." Recall counts are reported as filed in the FDA’s Enforcement Reports and represent individual product-level actions; a single field correction affecting multiple product codes or catalog numbers may register as multiple database entries. All counts represent active or registered listings in the FDA database as of July 2026.

Key Historical Milestones and M&A Impact

Baxter's regulatory footprint is a direct reflection of its corporate development. The company’s transition from an IV solution provider to a digital health and patient monitoring leader is marked by several landmark transactions, each introducing a distinct library of FDA registrations:

Milestone / Acquisition	Year	Clinical Segment	Regulatory Significance
Founding & IV Innovation	1931	Intravenous Therapy	Introduced the first commercially manufactured intravenous solutions; established early registrations for solution containers.
Althin Medical Acquisition	2000	Renal Care	Expanded hemodialysis registrations, introducing the Tina and Althin series dialyzers.
Gambro Acquisition ($4.0B)	2013	Renal Care / Dialysis	The second-largest acquisition in Baxter's history. Absorbed Gambro's massive hemodialysis and continuous renal replacement therapy (CRRT) portfolios.
Hillrom Acquisition ($10.5B)	2021	Connected Care, Beds, Monitoring	The largest acquisition in Baxter's history. Added Hillrom's smart hospital beds, Welch Allyn monitors, and the Life2000 ventilator platform.
Vantive Kidney Care Divestiture ($3.8B)	2026	Kidney Care	Baxter sold its Vantive Kidney Care segment (renal, dialysis, CRRT) to The Carlyle Group for $3.8B; the transaction closed January 31, 2026, removing the bulk of Baxter's renal regulatory footprint.
Life2000 Permanent Recall	2025	Ventilation / Connected Care	Baxter permanently removed the Life2000 ventilator system from the market over a Class I cybersecurity vulnerability.

This M&A history explains why Baxter's current database registrations are split across several legal entities. While new clearances are submitted under "Baxter Healthcare Corporation," hundreds of active 510(k)s and recalls remain listed under "Hill-Rom, Inc." or "Welch Allyn, Inc."

The Vantive Divestiture: Removing the Kidney Care Footprint

Baxter's corporate structure underwent a major reorganization in its Kidney Care segment. Baxter originally planned to spin off its Kidney Care business (Acute Therapies/CRRT and Renal Care/hemodialysis and peritoneal dialysis) as a standalone company named Vantive. In late 2025, however, Baxter instead signed a definitive agreement to sell the Vantive Kidney Care segment to private-equity firm The Carlyle Group for $3.8 billion, and the transaction closed on January 31, 2026. Vantive now operates as an independent kidney-care company under Carlyle ownership.

For hospital clinical engineering and regulatory leads, this divestiture directly affects how device registrations and field actions are routed:

Assets That Moved to Vantive: The divestiture transferred ownership of the peritoneal dialysis platforms (HomeChoice Claria and Amia automated cyclers) and the Gambro-derived ICU continuous renal-replacement systems (AK98, Prismaflex, and PrisMax platforms). These correspond to product codes such as KDI (hemodialysis system) and FJE (peritoneal dialysis cycler), which now fall under Vantive's separate FDA establishment registrations rather than Baxter's.
Remaining "New Baxter" Footprint: The residual Baxter entity is now focused on medication delivery systems (infusion pumps, IV solutions, and clinical nutrition), biosurgery products, and the connected-care hardware acquired from Hillrom (smart beds, patient monitors, and diagnostic tools under the Welch Allyn brand).
Recall Routing: Going forward, safety actions on the divested renal/dialysis platforms (e.g., Gambro AK 98 or Prismaflex corrections) are issued by Vantive rather than Baxter. Hospitals should update vendor and recall-notification contacts accordingly so that field-correction notices for these products reach the right clinical and biomedical teams.

The 510(k) Clearance Portfolio: General Hospital and Renal Care Dominance

The 510(k) pathway is the primary regulatory vehicle for Baxter, accounting for the vast majority of its commercialized devices. As of July 2026, Baxter holds 999 active 510(k) clearances in the FDA database.

When categorized by FDA medical specialty, the data reveals that Baxter’s portfolio is concentrated in clinical care consumables (General Hospital) and laboratory diagnostics (Gastroenterology/Urology), followed by interventional vascular products (Cardiovascular):

Medical Specialty	Clearance Count	Percentage of 510(k) Portfolio	Core Technologies
General Hospital	223	22.3%	Infusion pumps, administration sets, syringes, needles, clinical nutrition bags
Gastroenterology, Urology	185	18.5%	Peritoneal dialysis cyclers, dialyzers, urological catheters, drainage bags
Cardiovascular	147	14.7%	Hemodialysis blood lines, vascular access ports, pressure monitoring lines
Clinical Chemistry	86	8.6%	Clinical chemistry analyzers, blood gas syringes, specimen preservation
Microbiology	67	6.7%	Automated specimen processors, culture media, diagnostic assays
Anesthesiology	66	6.6%	Airway connectors, transport ventilators, anesthesia gas vaporizers
Other Specialties	225	22.6%	Patient monitors, surgical drapes, orthopedic surgical instruments
Total Active Clearances	999	100.0%

Detailed Product Code Directory: 510(k) Leaderboard

Baxter's top active 510(k) product codes highlight the company’s focus on laboratory diagnostics, vascular access, and medication delivery:

Product Code	Specialty	Regulatory Classification	Device Description	Key Baxter Brand Families	Active Clearances
FRN	General Hospital	Class II (21 CFR 880.5725)	Infusion Pump	Sigma Spectrum, Spectrum IQ, Alaris platforms	45
FPA	General Hospital	Class II (21 CFR 880.5440)	Intravascular Administration Set	Interlink, Clearlink administration sets	39
KDI	Gastroenterology	Class II (21 CFR 876.5820)	Hemodialysis System and Accessories	Gambro AK98, Artis, Phoenix dialysis machines	32
FKP	General Hospital	Class II (21 CFR 880.5200)	Intravenous Solution Container	Viaflex, Aviva solution containers	28
FJT	General Hospital	Class II (21 CFR 880.5570)	Hypodermic Single Lumen Needle	Baxter hypodermic needles	25
DQX	Cardiovascular	Class II (21 CFR 870.1280)	Catheter Guide Wire	Vascular access guide wires	22
JJE	Clinical Chemistry	Class II (21 CFR 862.1675)	Blood Specimen Collection Device	Vacutainer legacy tubes, blood gas syringes	21
LQR	Microbiology	Class II (21 CFR 866.3950)	Influenza Virus Nucleic Acid Test	Rapid diagnostic assays	18

The Premarket Approval (PMA) Portfolio: High-Risk Renal Systems

While Baxter's volume lies in 510(k)-cleared consumables, the company also manages a significant portfolio of high-risk Class III devices that require Premarket Approval (PMA).

Baxter holds 205 active PMA filings and supplements in the FDA database. Unlike peers such as Medtronic or Abbott, whose PMAs are dominated by active cardiac implants (like pacemakers and defibrillators), Baxter's PMA portfolio is comparatively small and concentrated in two areas: high-risk renal replacement therapy systems and specialized drug-delivery platforms.

Renal Care and Hemodialysis Systems: A substantial share of Baxter's PMAs historically sat with the Gambro and renal-care divisions. These include dialyzers and continuous renal replacement therapy (CRRT) systems used to treat acute kidney injury (AKI) in ICU settings, associated with product codes such as KDI (hemodialysis system) and FJE (peritoneal dialysis cycler) and the HomeChoice and Amia peritoneal dialysis platforms. Note that with the January 2026 Vantive divestiture, the renal PMA portfolio is transitioning to Vantive/Carlyle ownership.
Specialized Drug-Delivery Systems: Baxter's remaining PMA supplements cover high-risk infusion and drug-delivery platforms — including large-volume pump safety features and parenteral-nutrition compounding systems — reflecting the company's post-Vantive focus on medication delivery and clinical nutrition.

Post-Market Safety: Recall Risk, Root Causes, and 2025–2026 Class I Events

With one of the largest installed bases of medical consumables and automated equipment in the world, Baxter has a significant post-market regulatory footprint. According to FDA database records, Baxter has 865 FDA-registered recalls across its brand history.

Recall Distribution by Operating Entity

Analyzing recalls by the specific recalling entity reveals that post-market safety issues are concentrated in three main business areas: the core consumables division, the interventional vascular division, and the infusion/dispensing systems division:

Recalling Entity	Registered Recalls	Percentage of Recalls	Primary Affected Devices / Series
Baxter Healthcare Corporation	373	43.1%	Infusion pumps, IV bags, clinical nutrition, syringes
Baxter Healthcare Corp. Rt. (variants)	225	26.0%	Dialyzers, blood lines, peritoneal dialysis cyclers
Hill-Rom, Inc.	66	7.6%	Smart hospital beds, patient transfer lifts, ventilators
Welch Allyn, Inc.	33	3.8%	Patient monitors, thermometry, diagnostic scopes
Baxter Healthcare Renal Div	46	5.3%	Peritoneal dialysis solutions, automated cyclers
Other Baxter / acquired subsidiaries	122	14.2%	Novametrix, Gambro legal entities, regional divisions
Total Registered Recalls	865	100.0%

Recall Root Cause Analysis

A review of the root causes listed in the FDA database shows that Baxter's recalls are primarily driven by manufacturing process control issues (such as sterility failures or packaging defects in high-volume consumables) and design issues (including software bugs in automated systems):

Under Investigation by Firm: 198 recalls (often representing active files or recent events where a final root cause report has not been finalized)
Process Control Failures: 171 recalls (sterility breaches, particulate contamination, sealing defects)
Nonconforming Material / Components: 145 recalls (out-of-specification plastics, adhesive failures, raw material defects)
Device Design Issues: 84 recalls (mechanical vulnerabilities, physical tolerances, component fatigue)
Software Design Anomalies: 33 recalls (coding bugs, UI lag, sensor integration errors in infusion and dispensing systems)

Recent 2025–2026 Class I Safety Events

The FDA classifies recalls as Class I when there is a reasonable probability that the use of or exposure to the device will cause serious adverse health consequences or death. In 2025 and 2026, Baxter managed several high-profile Class I events:

Baxter Life2000 Ventilation System Permanent Removal (December 2025): Baxter permanently removed the Life2000 Ventilation System (acquired via Hillrom) from the market. This Class I action was initiated due to a cybersecurity vulnerability in the device's diagnostic software interface. The vulnerability could allow unauthorized access to the device's configuration settings, presenting a risk of altered ventilation parameters. The Life2000 line had already faced a 2024 field correction over a battery-charger dongle that could fail to charge the device; in April 2025 Baxter announced it would end manufacture, distribution, and service of the system, before the December 2025 permanent-removal notice instructed clinicians to cease use and transition patients to alternative ventilators.
Spectrum IQ Infusion System Software Correction (2025): Baxter issued a software correction for its Spectrum IQ Infusion System to address a programming error that could cause the pump to deliver incorrect titration rates. The FDA classified this action as a Class I recall due to the risk of over-infusion or under-infusion of critical medications.
Abacus Order Entry Software Update (Late 2025): The FDA classified a major field correction for Baxter's Abacus order entry software as a Class I action. The software, used to calculate ingredients for total parenteral nutrition (TPN) bags, contained an error that could result in incorrect dosing calculations for neonates.
Gambro AK 98 Hemodialysis System Update (May 2025): Baxter updated the software for the Gambro AK 98 hemodialysis system after reports that a pressure sensor malfunction could go undetected by the device's automated alarms. The correction was tagged as Class I due to the risk of air embolism during hemodialysis.

Action Plan for Healthcare Facilities and Biomed Teams

To minimize disruption during safety alerts, clinical engineering teams should implement the following protocols for Baxter products:

Recall Segmentation: Distinguish between legacy Baxter solutions (IV fluids) and capital hardware (pumps, dialysis machines, beds). Hardware issues often require software patches or component replacements that can be managed on-site, while solution recalls require physical inventory quarantine.
Infusion Pump Software Auditing: For platforms like the Spectrum IQ, establish a verification step in the CMMS to confirm that all units in circulation have received the latest software version, preventing firmware mismatch errors.
Renal Care Supplier Alignment: During the Vantive transition, confirm purchasing contracts and safety contact details to ensure that field correction notices are routed to the correct administrative and clinical departments.

The Global Manufacturing Footprint: Facilities and Registrations

Baxter operates a massive global supply chain to support its high-volume consumables and capital equipment lines. According to the FDA's Establishment Registration database, Baxter holds 480 registered device listings across its active manufacturing sites.

Primary US Manufacturing and Logistics Hubs

An analysis of Baxter's FDA-registered establishments in the United States reveals the geographical centers of its production capacity:

Round Lake, Illinois (161 registrations): This facility represents the manufacturing and product center for Baxter's intravenous solutions. Round Lake handles high-volume extrusion and assembly of IV bags, solution containers, and administrative sets.
Skaneateles Falls, New York (96 registrations): This facility represents the manufacturing center for Welch Allyn products. Skaneateles Falls handles the assembly and calibration of patient monitors, thermometry, and physical assessment tools.
Aibonito, Puerto Rico (53 registrations): A key manufacturing site for specialized surgical and drug delivery consumables. The Aibonito plant is responsible for producing component sets for critical care applications.
Batesville, Indiana (34 registrations): The primary hub for Baxter's smart hospital beds and patient handling solutions (acquired via Hillrom). Batesville produces frames, motors, and integrated mattress systems.
Andover, Massachusetts (32 registrations): Responsible for the engineering and production of advanced monitoring interfaces.
Birmingham, Alabama (31 registrations): Handles the assembly and sterilization of specialized solution containers and hemodialysis tubing.

International Manufacturing Footprint

Baxter's international manufacturing footprint includes key locations to support global markets:

Mexico (60 registrations): High-volume production of IV administration sets and general hospital consumables.
Malta (55 registrations): Specialized assembly and sterilization of dialyzers and blood lines.
Dominican Republic (48 registrations): Assembly of urological bags and clinical drapes.
Costa Rica (32 registrations): Micro-assembly of electronic patient monitoring modules.

Comparison of Baxter's FDA Footprint with Peers

Comparing Baxter's FDA footprint with its primary medtech peers highlights its unique product mix:

Metric	Baxter International	Becton Dickinson (BD)	Medtronic	Abbott Laboratories
Primary Regulatory Profile	Renal care & infusion systems	Lab diagnostics & general hospital consumables	High-risk active implants & surgical hardware	Diagnostics, diabetes care & structural heart
Active 510(k) Clearances	999	1,939	1,597	1,218
Active PMAs	205	302	12,805	5,617
FDA-Registered Recalls	865	1,470	1,897	909
Core 510(k) Specialties	General Hospital, Renal	Microbiology, General Hospital	Cardiovascular, Orthopedics	Clinical Chemistry, Cardio
Key Manufacturing Hubs	Illinois, New York, Puerto Rico	Georgia (Urology), Maryland (Diagnostics), California (Infusion)	Ireland, Minnesota, California	Illinois, California, Germany

Frequently Asked Questions (FAQ)

Is the Baxter Life2000 ventilator recall still active?

Yes. The Baxter Life2000 recall is a permanent removal action initiated in December 2025. Baxter has discontinued the Life2000 Ventilation System due to a combination of cybersecurity vulnerabilities and hardware reliability issues, instructing healthcare providers to cease use of the system and transition patients to alternative ventilation platforms.

Do Baxter's Hillrom and Welch Allyn products appear in the FDA footprint data?

Yes, they represent a significant portion of Baxter's modern FDA database footprint. Legacy Hillrom filings account for Baxter’s active registrations under patient handling and ventilation categories, and Welch Allyn remains the registered applicant for 33 recalls. The Hillrom acquisition introduced a massive library of connected care and patient monitoring registrations, with manufacturing concentrated at legacy hubs in Batesville, Indiana and Skaneateles Falls, New York.

Which Baxter infusion pumps have been recalled?

The most significant recalls for Baxter infusion pumps involve the Sigma Spectrum and Spectrum IQ platforms. These pumps have been subject to field corrections and software updates to address coding anomalies, keypad malfunctions, and titration calculation errors, all classified as Class I recalls due to the risk of under- or over-infusion of critical patient medications.

Conclusion and Regulatory Outlook for Baxter

Following the integration of the Hillrom acquisition and the January 2026 divestiture of its Kidney Care division (Vantive) to Carlyle, Baxter has transitioned into a focused MedTech supplier. By combining its medical delivery systems with Hillrom's smart hospital beds and patient monitoring systems, Baxter has streamlined its regulatory focus, concentrating on clinical care solutions, connected monitoring, and infusion therapies.

For hospital compliance and procurement teams, managing a relationship with Baxter requires ongoing monitoring of its core manufacturing centers in Illinois and New York. While the company's high-volume consumables drive a high absolute recall count in the FDA database, its clinical utility remains a cornerstone of modern hospital operations.

Disclaimer: The regulatory data and analysis presented in this report are for educational and informational purposes only. MedDeviceGuide does not provide legal, regulatory, or quality-system compliance advice for specific medical products or manufacturers. For official regulatory filings and current recall statuses, consult the U.S. FDA’s public databases.